{"ticker": {"uuid": "29bf9f18-c50e-4273-a8aa-fa10f2d40aa0", "symbol": "ACOG", "name": "Alpha Cognition Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Raymond James Starts Alpha Cognition (ACOG) at Outperform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxONGw1cXIyZkZWRmVFN2FnclNGVGFCTFg1VktvM0ZMZFNQU0ZEOFNfYmRFSGtXT2VHcVhRODd4LVNLRFk0UGRYdERaSUVKYkdtMjhONTFqOGE0Tko5RVM2dHJqejhVYzdrMUd0aUN4ckEwT0trc3ZJaTNEQ1plNU1LeUxkcy13NUJ0UnplN1MzSUQ1VndyNHVycDQtVlBZVDY0TXRn?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:08:36+00:00", "published_display": "14 Jul 2026 18:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alpha Cognition (ACOG) Stock Fair Value Moves Lower As Analysts Weigh Zunveyl Persistence", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMWtqeWFma0ItU2ppXzV5YUQ0SFJETVpadDJfUFJ6Vk1XOTY0ZXBxd1RMc0lVZHJ5WTl5RHpOeFVuTGZOYTFXZzNrT1MtbHRaa0JuNjlJbkdBb0ZnSHJUZUp1djV1YTBLQVJtZ3Y3MmlJMUNpb3I0TW9EZ0xYbmNyQm84MWJ5blREWW1zQTZ0b3ZBT0dCOFkzQ0ItWTA?oc=5", "source_name": "Market source", "published_at": "2026-07-11T22:08:16+00:00", "published_display": "11 Jul 2026 22:08", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James initiates Alpha Cognition stock coverage with outperform rating", "summary": "Raymond James has initiated coverage of Alpha Cognition Inc. (NASDAQ: ACOG) with an Outperform rating and a $20.00 price target, highlighting the potential of its Alzheimer's drug Zunveyl. The stock is currently trading below the consensus target, with InvestingPro data suggestin", "url": "https://ng.investing.com/news/stock-market-news/raymond-james-initiates-alpha-cognition-stock-coverage-with-outperform-rating-93CH-2594665", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T00:09:11", "published_display": "11 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Initiated at Outperform by Raymond James", "summary": "Raymond James has initiated coverage on Alpha Cognition (NASDAQ: ACOGF) with an \"Outperform\" rating. This news suggests a positive outlook from the financial firm regarding the company's future performance.", "url": "https://www.moomoo.com/news/post/72779471/alpha-cognition-initiated-at-outperform-by-raymond-james", "source_name": "Moomoo", "published_at": "2026-07-10T13:13:30", "published_display": "10 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit", "summary": "Alpha Cognition Inc. announced that its CEO, Michael McFadden, will participate in a Late-Stage & Commercial CNS Small Cap panel discussion at the B. Riley Securities Mind, Muscle & Vision Summit on July 16th in Boston. The company focuses on developing therapies for neurodegener", "url": "https://www.businesswire.com/news/home/20260710156704/en/Alpha-Cognition-to-Participate-in-Panel-Discussion-at-the-B.-Riley-Securities-Mind-Muscle-Vision-Summit", "source_name": "Business Wire", "published_at": "2026-07-10T12:39:23", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Alpha Cognition Inc. \u2013 NASDAQ:ACOG", "summary": "This article provides financial data for Alpha Cognition Inc. (NASDAQ: ACOG), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a data point from a larger financial platform, offering a snapshot of the company's valuation metric. The content it", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T17:09:33", "published_display": "07 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACOG - Alpha Cognition Inc Latest SEC Filings", "summary": "This article provides key financial data for Alpha Cognition Inc (ACOG), including its latest stock performance, market capitalization, income, sales, and employee count. It also details various financial ratios, insider and institutional ownership, profitability margins, and ana", "url": "https://finviz.com/stock?t=ACOG&p=d&ty=lf&page=1", "source_name": "Finviz", "published_at": "2026-07-06T16:39:54", "published_display": "06 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alpha Cognition Inc. \u2013 NASDAQ:ACOG", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Alpha Cognition Inc. (NASDAQ: ACOG). It appears to be a stub or a pre-filled template from TradingView, providing financial page structure without specific data points in the provided content. The articl", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:09:15", "published_display": "05 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alpha Cognition Inc. \u2013 NASDAQ:ACOG", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Alpha Cognition Inc. (NASDAQ: ACOG). It presents this specific financial data point as part of the company's financial overview on TradingView. The content is primarily a data page, providing the metric wit", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:41:04", "published_display": "04 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc Actuals & Estimates (NASDAQ:ACOG)", "summary": "This article provides an overview of Alpha Cognition Inc. (NASDAQ: ACOG) financials and analyst estimates. It covers historical stock performance, price forecasts, earnings reports, revenue, market capitalization, and volatility, highlighting that ACOG does not pay dividends and ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:27", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACOG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Alpha Cognition Inc. (ACOG) stock, including analyst price targets, financial performance, and historical stock data. It summarizes current and predicted earnings per share and revenue, notes the stock's volatility and market capitalization, a", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:27", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Alpha Cognition Inc. For: 23 June By Investing.com", "summary": "This article is a brief announcement from Investing.com about Alpha Cognition Inc.'s Form 8K filing for June 23. It includes a stock price mention for ACOG and is primarily a placeholder for the SEC filing information. The content also features various market data, trending stock", "url": "https://ng.investing.com/news/stock-market-news/form-8k-alpha-cognition-inc-for-23-june-93CH-2570420", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T05:41:51", "published_display": "24 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board", "summary": "Alpha Cognition Inc. announced that Dr. Robert Wills has been elected Chairman of its Board of Directors, succeeding Len Mertz. Dr. Wills brings extensive experience from his previous roles at Johnson & Johnson and various other pharmaceutical companies, and has been on Alpha Cog", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MIST/pressreleases/2602609/alpha-cognition-announces-election-of-dr-robert-wills-as-chairman-of-the-board/", "source_name": "The Globe and Mail", "published_at": "2026-06-23T20:09:32", "published_display": "23 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition names Robert Wills as board chairman", "summary": "Alpha Cognition Inc. (NASDAQ:ACOG) has appointed Robert Wills as its new Chairman of the Board, replacing Len Mertz. Wills has extensive experience in the biopharmaceutical industry, previously serving on Alpha Cognition's board since 2025 and holding leadership roles at other co", "url": "https://www.investing.com/news/company-news/alpha-cognition-names-robert-wills-as-board-chairman-93CH-4755580", "source_name": "Investing.com", "published_at": "2026-06-23T19:09:30", "published_display": "23 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Elects Biopharma Veteran Dr. Robert Wills as Board Chairman", "summary": "Alpha Cognition Inc. has appointed biopharma veteran Dr. Robert Wills as the new chairman of its board of directors, succeeding Len Mertz. Dr. Wills brings extensive experience from Johnson & Johnson and various board leadership roles at other pharmaceutical companies, which will", "url": "https://www.citybiz.co/article/864652/alpha-cognition-elects-biopharma-veteran-dr-robert-wills-as-board-chairman/", "source_name": "citybiz", "published_at": "2026-06-23T18:09:30", "published_display": "23 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Files 8-K Announcing Officer Changes and Shareholder Voting Results \u2013 June 2026", "summary": "Alpha Cognition Inc. (ACOG) has filed an 8-K report detailing the results of its recent shareholder meeting, including the election of six directors and the ratification of CBIZ CPAs P.C. as their independent registered public accounting firm. The company also confirmed its statu", "url": "https://www.minichart.com.sg/2026/06/23/alpha-cognition-inc-acog-files-8-k-announcing-officer-changes-and-shareholder-voting-results-june-2026/", "source_name": "Minichart", "published_at": "2026-06-23T15:40:26", "published_display": "23 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Elects Robert Wills as Board Chairman", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alpha-cognition-elects-robert-wills-130348698.html", "source_name": "MT Newswires", "published_at": "2026-06-23T13:03:48+00:00", "published_display": "23 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026", "summary": "Alpha Cognition (Nasdaq: ACOG) is scheduled to report its first quarter 2026 financial results on Thursday, May 14, 2026. The company will also provide a business update, likely covering advancements in its clinical programs or strategic initiatives. This announcement will be of ", "url": "https://www.moomoo.com/news/post/69051893/press-release-alpha-cognition-nasdaq-acog-to-report-first-quarter", "source_name": "Moomoo", "published_at": "2026-06-22T05:12:08", "published_display": "22 Jun 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Share Price - ACOGF, RNS News, Articles, Quotes, & Charts (OTCMKTS:ACOGF)", "summary": "Alpha Cognition (OTCMKTS: ACOGF) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). Their product ALPHA-1062 is being developed for Alzheimer's, while ALP", "url": "https://www.proactiveinvestors.com/OTCMKTS:ACOGF/Alpha-Cognition", "source_name": "Proactive financial news", "published_at": "2026-06-20T15:41:01", "published_display": "20 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Keeps Their Buy Rating on Alpha Cognition Inc (ACOG)", "summary": "Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Alpha Cognition Inc. (ACOG), with the company showing strong insider sentiment and a significant upside potential according to the average analyst price target. Despite reporting a GAAP net loss of $6.48 million ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2552369/craig-hallum-keeps-their-buy-rating-on-alpha-cognition-inc-acog/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T04:09:36", "published_display": "20 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Insiders Still US$88k Away From Original Investment Value", "summary": "Insiders at Alpha Cognition (NASDAQ: ACOG) purchased US$397.5k worth of shares in the past year, but their investment is still down by US$88k, despite a recent 12% price gain. The largest purchase was by Independent Chairman Len Mertz for US$250k at US$9.00 per share, indicating ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acog/alpha-cognition/news/alpha-cognition-insiders-still-us88k-away-from-original-inve", "source_name": "Simply Wall Street", "published_at": "2026-06-18T10:39:53", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc (ACOG) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Alpha Cognition Inc (ACOG). It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also presents current stock performance d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acog/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T12:11:33", "published_display": "17 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s drug ZUNVEYL to be tested in real-world use through Q2 2027", "summary": "Alpha Cognition has enrolled the first patient in its RESOLVE Phase 4 post-marketing clinical study for ZUNVEYL, an FDA-approved Alzheimer's drug. This study aims to further evaluate the drug's tolerability and treatment experience in real-world clinical practice, collecting safe", "url": "https://www.stocktitan.net/news/ACOG/alpha-cognition-announces-first-patient-enrolled-in-resolve-phase-4-bv0aoj0579ym.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:40:54", "published_display": "17 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL\u00ae in Patients with Mild to Moderate Alzheimer\u2019s Disease", "summary": "Alpha Cognition has announced the enrollment of the first patient in its RESOLVE Phase 4 clinical study for ZUNVEYL\u00ae, a treatment for mild to moderate Alzheimer's disease. This post-marketing study aims to further assess the tolerability profile and treatment experience of ZUNVEY", "url": "https://www.biospace.com/press-releases/alpha-cognition-announces-first-patient-enrolled-in-resolve-phase-4-study-evaluating-zunveyl-in-patients-with-mild-to-moderate-alzheimers-disease", "source_name": "BioSpace", "published_at": "2026-06-16T14:09:23", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition's Phase 4 Trial of Zunveyl Completes Patient Enrollment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-cognition-apos-phase-4-125645386.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:56:45+00:00", "published_display": "16 Jun 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition enrolls first patient in ZUNVEYL phase 4 study", "summary": "Alpha Cognition Inc. has enrolled the first patient in its Phase 4 post-marketing clinical study, RESOLVE, for its FDA-approved Alzheimer's treatment, ZUNVEYL. This multicenter study will evaluate the tolerability and safety profile of ZUNVEYL in routine clinical practice for pat", "url": "https://www.investing.com/news/company-news/alpha-cognition-enrolls-first-patient-in-zunveyl-phase-4-study-93CH-4744891", "source_name": "Investing.com", "published_at": "2026-06-16T13:09:23", "published_display": "16 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition enrolls first patient in ZUNVEYL phase 4 study By Investing.com", "summary": "Alpha Cognition Inc. has enrolled the first patient in its Phase 4 clinical study, RESOLVE, for ZUNVEYL, an FDA-approved treatment for mild to moderate Alzheimer\u2019s disease. The study aims to evaluate ZUNVEYL's tolerability in routine clinical practice and monitor safety, treatmen", "url": "https://ca.investing.com/news/stock-market-news/alpha-cognition-enrolls-first-patient-in-zunveyl-phase-4-study-93CH-4693457", "source_name": "Investing.com Canada", "published_at": "2026-06-16T13:02:43", "published_display": "16 Jun 2026 13:02", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Alpha Cognition (NASDAQ:ACOG) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPR2N5eTJ2X0NaaU9sTE1VOUpWSnFnQmtlWVF2Q2xZQVhBWXBteUJYbDJ3Z1o0RzJVU0VXdkh2ZUNqMmpNMG9MdDdjb0ppbDJRREJEN2xDcHY3UjFRNTRuZVRVZWZMY3NkRzQxWHBSeFZKcVFYLVBzNlFxME1CbkE1TEoxek8zTm8wSTlKNHJmdWh0cHN3bGhrQThTbnc2RW8?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Says Alzheimer's Therapy Shows Improvement in Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-cognition-says-alzheimer-apos-133149065.html", "source_name": "MT Newswires", "published_at": "2026-06-09T13:31:49+00:00", "published_display": "09 Jun 2026 13:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL\u00ae in Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-cognition-reports-positive-top-120000192.html", "source_name": "Business Wire", "published_at": "2026-06-09T12:00:00+00:00", "published_display": "09 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (NASDAQ:ACOG) Just Reported, And Analysts Assigned A US$16.00 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQcG5lOGg5ZENKTldYWUFVVFI4cG9BS2pQYWRnTzMyeERkcXRIT3YyVlFIZzlzcUs2c2hNbjZITWJzWFFId21qTlBub1pvckhnclhMd01aTWhlSk1TLUROSGNBZGo0ZmkxZTRiQXdEU1NhUGJIYWNSNFN4bkJqZ3M1TElieG1ydGhEcXRWMlBCczY2VGZrRWVrbmVaYkE?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ALPHA COGNITION ($ACOG) Releases Q1 2026 Earnings, Stock Rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNOTV0T3pvR0ZyUnhrQVBtY2Jmc3Q1SllTMFFoSk9IclI3NV9oZUZsTkVlQk1weklRS2hMN2JLczNVSGN0akZCbjRVSDlkT3NMN25LZ2l1bEZYNkNwdkZhTFFPZHJOaUNXb2hCZ210VTlwT2UwTVVFVFZBZFNEMGNVM3JCRkoybXdSY1RMVkZ2ckxJTGxtRmd1UzNVMExYZkE2cjlVa0dB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPbDQ1SXBQMEdVUWhCV1VLejBacVYzcmVqc0d5aUVtSkIyYkJYRlZ2dlVUcjdkSjhtYWY2R2NRN0N2Ui1kVGl2VFA1QVZhY1FPUXkwcmpzWEctMHJrT2d1bWFydGVUQ2pfT1BQc0hWTU4zdFBQYTVzTzA0VVJrV21kYnRYbHVSbnQtS085UU5vWWJERnY1VzZ1bWhwM2xUdw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQOFRYZ0Y2cmFnTllVMHR5Q2pnTWotb1ZHUmUxNTFPZGxtTjczenlNbXBHRklTeHNZbjRpNndMNm5Rcmotb01rcV9vWGs4UEk5UFNKbmFXeV9ubklNS2RDNFJJbEt2WU1BWG9qbWhFcEVjYUwzaGtkY2JCb0dqajU1VmhJemNOeUdlZjlMNVZ5cHhJbnlYR2xaeldDT2k5NGc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alpha Cognition Inc.'s (NASDAQ:ACOG) Path To Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVXlOXy1tem1FTlRqc1I2UTNrSmR2OWtCU1RVamNrSHFINzV4SFN5N3o5eEVET0RGcndLcU0wclh2LUlEb0JkMzhETjR5bUdJZGVrR0gxTUVIejhFYzJtWG5NNG1GRnRkalNxX0hjRkxkOHJENThzWUlPZTFNRzhUYmNSQ3lWSm1sQXBmSENPOEF6MU5zVFJncFV1ZTJ0RUdUNVE?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNelBDVk9QRl9iMWVGYjhnQlp2YzhJQlFVWldGTlBxeFdqTlJ4MWlyNnhjZE4xMXRiTkZ2V0R2TmJxaUhLclR3UFFHcEo5cHBtelFMaTR4dlFUZ0p1b1BiWnBXVndUN0dBWmZsSTZSUlYwOGcwblhaT0Z5WXFFZ2NMWHNBWVFoTnlHVmg1UGNB?oc=5", "source_name": "qz.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQcWhMSU8yZEZCaVY1RkV6RXdoWUZOeEpqOThrbktDNV9CRkhza1ZDeFBRSHQwYWZHbG1mSjE3dHc3Smp0SUpjdVRPcHdOVE5OSVhtdnRfUDIwOWV5cmpqcC1PSnMwcTFVSlFXYnluWnJ5RlplSEtneGMwMTA5VVdqcDlCRWJaMGpDMEFGOXMwZDNfQ2o2SWlRTlJpVl9qMlVoa1pENmVObGtVMFlDRjY2TEpScmw1bVFWOWRzTnI5SjQ2eDl3T1gzVg?oc=5", "source_name": "BioSpace", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALPHA COGNITION ($ACOG) Releases Q4 2025 Earnings | ACOG Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPbHc0MTJuMmhCZ3lVUzNsM3pGZkVRb18ta1BaR2VqbXpONWw3NkprN1hKbktlcGM1eU91ZjlIMmxsT3VQUjJxeHhQb0lVOGM4aWhFZ1pxc2VXb1AtQzc2WC1BcjhyNW9hVERBYWJlNkdheUFROER0WnYzQW5kWXZUN1pELURXdmdhQVJHMVN1bnZkUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNZ3FDN1ZZMFduTGxaUWZkWXBENlpDVEd5Y1hFcTBXZUJ3NEtLdE5HLWR5bXpRRzZ0MjhiZmdMV0NkTThFcWVJaUlRZHBiQkN0dkctcGVBNjhrZnRQMG0tLU9GOVVVdWtpRWV4d3FvM3NjRV9SaVlQN1BtWnB6cnZHNHExa2ozTGg1aTB2djBJek9EVWlJdzNlT0lUUW4yZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOekZTbUdSVEU0d2VYMk1HdTNqTnJWbG1fRWhYdlR1S0E0dGJiNUczNW8wTGxoa21oWTNhZFlrQV9VSGZzdUIwOFY5cE5HcWNEMEF5bkZ4bFUzNkNzckJ5Ulg3cFBuNE9lcElNRExQMkRUVEd2N0V4bDdFUWt5N1pNcDNVVnd5SGxTdGY4LXlmSU1hVnBDUjhXVUhONmRvWXdmMUJwejJlaV9KMl9oSTQ5aGZvbEdXV0dLRDZtaDVESUVlVEJpWmhlMVBDSlJUR1hrdnJhMjBOQkNwbnFSQTZ6U1d5eUpLVF94MnhTRERjUVBhYms?oc=5", "source_name": "Business Wire", "published_at": "2024-10-31T07:00:00+00:00", "published_display": "31 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approves Alpha Cognition\u2019s Zunveyl as Oral Therapy for Mild-to-Moderate Alzheimer Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNdVVLY1A4dlk3Qk9yUGlTbFNTdktYZzJJZXlPRno3MXNOUWstRkFKUl9WMDg3OVNCYkdCQkpqNC1mel9yY08tRFVjUFJLTTNFNDJwd0hDZ040a211UHgtbDlfd2Q2d2pCM19UcnNHTkxrMDl1SFhqcDZJRzM4cjRzbDV3ZWVDWnpqOFpYVlVNb0l2YUJuOXJKWEJlRWl2b1JvX3JFUXR4cE9wZ3JYYUlfYmlB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2024-07-29T07:00:00+00:00", "published_display": "29 Jul 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Raymond James Starts Alpha Cognition (ACOG) at Outperform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxONGw1cXIyZkZWRmVFN2FnclNGVGFCTFg1VktvM0ZMZFNQU0ZEOFNfYmRFSGtXT2VHcVhRODd4LVNLRFk0UGRYdERaSUVKYkdtMjhONTFqOGE0Tko5RVM2dHJqejhVYzdrMUd0aUN4ckEwT0trc3ZJaTNEQ1plNU1LeUxkcy13NUJ0UnplN1MzSUQ1VndyNHVycDQtVlBZVDY0TXRn?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:08:36+00:00", "published_display": "14 Jul 2026 18:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition (ACOG) Stock Fair Value Moves Lower As Analysts Weigh Zunveyl Persistence", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMWtqeWFma0ItU2ppXzV5YUQ0SFJETVpadDJfUFJ6Vk1XOTY0ZXBxd1RMc0lVZHJ5WTl5RHpOeFVuTGZOYTFXZzNrT1MtbHRaa0JuNjlJbkdBb0ZnSHJUZUp1djV1YTBLQVJtZ3Y3MmlJMUNpb3I0TW9EZ0xYbmNyQm84MWJ5blREWW1zQTZ0b3ZBT0dCOFkzQ0ItWTA?oc=5", "source_name": "Market source", "published_at": "2026-07-11T22:08:16+00:00", "published_display": "11 Jul 2026 22:08", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raymond James initiates Alpha Cognition stock coverage with outperform rating", "summary": "Raymond James has initiated coverage of Alpha Cognition Inc. (NASDAQ: ACOG) with an Outperform rating and a $20.00 price target, highlighting the potential of its Alzheimer's drug Zunveyl. The stock is currently trading below the consensus target, with InvestingPro data suggestin", "url": "https://ng.investing.com/news/stock-market-news/raymond-james-initiates-alpha-cognition-stock-coverage-with-outperform-rating-93CH-2594665", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T00:09:11", "published_display": "11 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Initiated at Outperform by Raymond James", "summary": "Raymond James has initiated coverage on Alpha Cognition (NASDAQ: ACOGF) with an \"Outperform\" rating. This news suggests a positive outlook from the financial firm regarding the company's future performance.", "url": "https://www.moomoo.com/news/post/72779471/alpha-cognition-initiated-at-outperform-by-raymond-james", "source_name": "Moomoo", "published_at": "2026-07-10T13:13:30", "published_display": "10 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit", "summary": "Alpha Cognition Inc. announced that its CEO, Michael McFadden, will participate in a Late-Stage & Commercial CNS Small Cap panel discussion at the B. Riley Securities Mind, Muscle & Vision Summit on July 16th in Boston. The company focuses on developing therapies for neurodegener", "url": "https://www.businesswire.com/news/home/20260710156704/en/Alpha-Cognition-to-Participate-in-Panel-Discussion-at-the-B.-Riley-Securities-Mind-Muscle-Vision-Summit", "source_name": "Business Wire", "published_at": "2026-07-10T12:39:23", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Alpha Cognition Inc. \u2013 NASDAQ:ACOG", "summary": "This article provides financial data for Alpha Cognition Inc. (NASDAQ: ACOG), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a data point from a larger financial platform, offering a snapshot of the company's valuation metric. The content it", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T17:09:33", "published_display": "07 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACOG - Alpha Cognition Inc Latest SEC Filings", "summary": "This article provides key financial data for Alpha Cognition Inc (ACOG), including its latest stock performance, market capitalization, income, sales, and employee count. It also details various financial ratios, insider and institutional ownership, profitability margins, and ana", "url": "https://finviz.com/stock?t=ACOG&p=d&ty=lf&page=1", "source_name": "Finviz", "published_at": "2026-07-06T16:39:54", "published_display": "06 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alpha Cognition Inc. \u2013 NASDAQ:ACOG", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Alpha Cognition Inc. (NASDAQ: ACOG). It appears to be a stub or a pre-filled template from TradingView, providing financial page structure without specific data points in the provided content. The articl", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:09:15", "published_display": "05 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alpha Cognition Inc. \u2013 NASDAQ:ACOG", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Alpha Cognition Inc. (NASDAQ: ACOG). It presents this specific financial data point as part of the company's financial overview on TradingView. The content is primarily a data page, providing the metric wit", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:41:04", "published_display": "04 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc Actuals & Estimates (NASDAQ:ACOG)", "summary": "This article provides an overview of Alpha Cognition Inc. (NASDAQ: ACOG) financials and analyst estimates. It covers historical stock performance, price forecasts, earnings reports, revenue, market capitalization, and volatility, highlighting that ACOG does not pay dividends and ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:27", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACOG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Alpha Cognition Inc. (ACOG) stock, including analyst price targets, financial performance, and historical stock data. It summarizes current and predicted earnings per share and revenue, notes the stock's volatility and market capitalization, a", "url": "https://www.tradingview.com/symbols/NASDAQ-ACOG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:27", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Alpha Cognition Inc. For: 23 June By Investing.com", "summary": "This article is a brief announcement from Investing.com about Alpha Cognition Inc.'s Form 8K filing for June 23. It includes a stock price mention for ACOG and is primarily a placeholder for the SEC filing information. The content also features various market data, trending stock", "url": "https://ng.investing.com/news/stock-market-news/form-8k-alpha-cognition-inc-for-23-june-93CH-2570420", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T05:41:51", "published_display": "24 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board", "summary": "Alpha Cognition Inc. announced that Dr. Robert Wills has been elected Chairman of its Board of Directors, succeeding Len Mertz. Dr. Wills brings extensive experience from his previous roles at Johnson & Johnson and various other pharmaceutical companies, and has been on Alpha Cog", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MIST/pressreleases/2602609/alpha-cognition-announces-election-of-dr-robert-wills-as-chairman-of-the-board/", "source_name": "The Globe and Mail", "published_at": "2026-06-23T20:09:32", "published_display": "23 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition names Robert Wills as board chairman", "summary": "Alpha Cognition Inc. (NASDAQ:ACOG) has appointed Robert Wills as its new Chairman of the Board, replacing Len Mertz. Wills has extensive experience in the biopharmaceutical industry, previously serving on Alpha Cognition's board since 2025 and holding leadership roles at other co", "url": "https://www.investing.com/news/company-news/alpha-cognition-names-robert-wills-as-board-chairman-93CH-4755580", "source_name": "Investing.com", "published_at": "2026-06-23T19:09:30", "published_display": "23 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Elects Biopharma Veteran Dr. Robert Wills as Board Chairman", "summary": "Alpha Cognition Inc. has appointed biopharma veteran Dr. Robert Wills as the new chairman of its board of directors, succeeding Len Mertz. Dr. Wills brings extensive experience from Johnson & Johnson and various board leadership roles at other pharmaceutical companies, which will", "url": "https://www.citybiz.co/article/864652/alpha-cognition-elects-biopharma-veteran-dr-robert-wills-as-board-chairman/", "source_name": "citybiz", "published_at": "2026-06-23T18:09:30", "published_display": "23 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Files 8-K Announcing Officer Changes and Shareholder Voting Results \u2013 June 2026", "summary": "Alpha Cognition Inc. (ACOG) has filed an 8-K report detailing the results of its recent shareholder meeting, including the election of six directors and the ratification of CBIZ CPAs P.C. as their independent registered public accounting firm. The company also confirmed its statu", "url": "https://www.minichart.com.sg/2026/06/23/alpha-cognition-inc-acog-files-8-k-announcing-officer-changes-and-shareholder-voting-results-june-2026/", "source_name": "Minichart", "published_at": "2026-06-23T15:40:26", "published_display": "23 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Elects Robert Wills as Board Chairman", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alpha-cognition-elects-robert-wills-130348698.html", "source_name": "MT Newswires", "published_at": "2026-06-23T13:03:48+00:00", "published_display": "23 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026", "summary": "Alpha Cognition (Nasdaq: ACOG) is scheduled to report its first quarter 2026 financial results on Thursday, May 14, 2026. The company will also provide a business update, likely covering advancements in its clinical programs or strategic initiatives. This announcement will be of ", "url": "https://www.moomoo.com/news/post/69051893/press-release-alpha-cognition-nasdaq-acog-to-report-first-quarter", "source_name": "Moomoo", "published_at": "2026-06-22T05:12:08", "published_display": "22 Jun 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Share Price - ACOGF, RNS News, Articles, Quotes, & Charts (OTCMKTS:ACOGF)", "summary": "Alpha Cognition (OTCMKTS: ACOGF) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). Their product ALPHA-1062 is being developed for Alzheimer's, while ALP", "url": "https://www.proactiveinvestors.com/OTCMKTS:ACOGF/Alpha-Cognition", "source_name": "Proactive financial news", "published_at": "2026-06-20T15:41:01", "published_display": "20 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Keeps Their Buy Rating on Alpha Cognition Inc (ACOG)", "summary": "Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Alpha Cognition Inc. (ACOG), with the company showing strong insider sentiment and a significant upside potential according to the average analyst price target. Despite reporting a GAAP net loss of $6.48 million ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2552369/craig-hallum-keeps-their-buy-rating-on-alpha-cognition-inc-acog/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T04:09:36", "published_display": "20 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Insiders Still US$88k Away From Original Investment Value", "summary": "Insiders at Alpha Cognition (NASDAQ: ACOG) purchased US$397.5k worth of shares in the past year, but their investment is still down by US$88k, despite a recent 12% price gain. The largest purchase was by Independent Chairman Len Mertz for US$250k at US$9.00 per share, indicating ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acog/alpha-cognition/news/alpha-cognition-insiders-still-us88k-away-from-original-inve", "source_name": "Simply Wall Street", "published_at": "2026-06-18T10:39:53", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc (ACOG) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Alpha Cognition Inc (ACOG). It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also presents current stock performance d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acog/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T12:11:33", "published_display": "17 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s drug ZUNVEYL to be tested in real-world use through Q2 2027", "summary": "Alpha Cognition has enrolled the first patient in its RESOLVE Phase 4 post-marketing clinical study for ZUNVEYL, an FDA-approved Alzheimer's drug. This study aims to further evaluate the drug's tolerability and treatment experience in real-world clinical practice, collecting safe", "url": "https://www.stocktitan.net/news/ACOG/alpha-cognition-announces-first-patient-enrolled-in-resolve-phase-4-bv0aoj0579ym.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:40:54", "published_display": "17 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL\u00ae in Patients with Mild to Moderate Alzheimer\u2019s Disease", "summary": "Alpha Cognition has announced the enrollment of the first patient in its RESOLVE Phase 4 clinical study for ZUNVEYL\u00ae, a treatment for mild to moderate Alzheimer's disease. This post-marketing study aims to further assess the tolerability profile and treatment experience of ZUNVEY", "url": "https://www.biospace.com/press-releases/alpha-cognition-announces-first-patient-enrolled-in-resolve-phase-4-study-evaluating-zunveyl-in-patients-with-mild-to-moderate-alzheimers-disease", "source_name": "BioSpace", "published_at": "2026-06-16T14:09:23", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition's Phase 4 Trial of Zunveyl Completes Patient Enrollment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alpha-cognition-apos-phase-4-125645386.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:56:45+00:00", "published_display": "16 Jun 2026 12:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition enrolls first patient in ZUNVEYL phase 4 study", "summary": "Alpha Cognition Inc. has enrolled the first patient in its Phase 4 post-marketing clinical study, RESOLVE, for its FDA-approved Alzheimer's treatment, ZUNVEYL. This multicenter study will evaluate the tolerability and safety profile of ZUNVEYL in routine clinical practice for pat", "url": "https://www.investing.com/news/company-news/alpha-cognition-enrolls-first-patient-in-zunveyl-phase-4-study-93CH-4744891", "source_name": "Investing.com", "published_at": "2026-06-16T13:09:23", "published_display": "16 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition enrolls first patient in ZUNVEYL phase 4 study By Investing.com", "summary": "Alpha Cognition Inc. has enrolled the first patient in its Phase 4 clinical study, RESOLVE, for ZUNVEYL, an FDA-approved treatment for mild to moderate Alzheimer\u2019s disease. The study aims to evaluate ZUNVEYL's tolerability in routine clinical practice and monitor safety, treatmen", "url": "https://ca.investing.com/news/stock-market-news/alpha-cognition-enrolls-first-patient-in-zunveyl-phase-4-study-93CH-4693457", "source_name": "Investing.com Canada", "published_at": "2026-06-16T13:02:43", "published_display": "16 Jun 2026 13:02", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Alpha Cognition (NASDAQ:ACOG) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPR2N5eTJ2X0NaaU9sTE1VOUpWSnFnQmtlWVF2Q2xZQVhBWXBteUJYbDJ3Z1o0RzJVU0VXdkh2ZUNqMmpNMG9MdDdjb0ppbDJRREJEN2xDcHY3UjFRNTRuZVRVZWZMY3NkRzQxWHBSeFZKcVFYLVBzNlFxME1CbkE1TEoxek8zTm8wSTlKNHJmdWh0cHN3bGhrQThTbnc2RW8?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Says Alzheimer's Therapy Shows Improvement in Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-cognition-says-alzheimer-apos-133149065.html", "source_name": "MT Newswires", "published_at": "2026-06-09T13:31:49+00:00", "published_display": "09 Jun 2026 13:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL\u00ae in Alzheimer\u2019s Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alpha-cognition-reports-positive-top-120000192.html", "source_name": "Business Wire", "published_at": "2026-06-09T12:00:00+00:00", "published_display": "09 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (NASDAQ:ACOG) Just Reported, And Analysts Assigned A US$16.00 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQcG5lOGg5ZENKTldYWUFVVFI4cG9BS2pQYWRnTzMyeERkcXRIT3YyVlFIZzlzcUs2c2hNbjZITWJzWFFId21qTlBub1pvckhnclhMd01aTWhlSk1TLUROSGNBZGo0ZmkxZTRiQXdEU1NhUGJIYWNSNFN4bkJqZ3M1TElieG1ydGhEcXRWMlBCczY2VGZrRWVrbmVaYkE?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALPHA COGNITION ($ACOG) Releases Q1 2026 Earnings, Stock Rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNOTV0T3pvR0ZyUnhrQVBtY2Jmc3Q1SllTMFFoSk9IclI3NV9oZUZsTkVlQk1weklRS2hMN2JLczNVSGN0akZCbjRVSDlkT3NMN25LZ2l1bEZYNkNwdkZhTFFPZHJOaUNXb2hCZ210VTlwT2UwTVVFVFZBZFNEMGNVM3JCRkoybXdSY1RMVkZ2ckxJTGxtRmd1UzNVMExYZkE2cjlVa0dB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPbDQ1SXBQMEdVUWhCV1VLejBacVYzcmVqc0d5aUVtSkIyYkJYRlZ2dlVUcjdkSjhtYWY2R2NRN0N2Ui1kVGl2VFA1QVZhY1FPUXkwcmpzWEctMHJrT2d1bWFydGVUQ2pfT1BQc0hWTU4zdFBQYTVzTzA0VVJrV21kYnRYbHVSbnQtS085UU5vWWJERnY1VzZ1bWhwM2xUdw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQOFRYZ0Y2cmFnTllVMHR5Q2pnTWotb1ZHUmUxNTFPZGxtTjczenlNbXBHRklTeHNZbjRpNndMNm5Rcmotb01rcV9vWGs4UEk5UFNKbmFXeV9ubklNS2RDNFJJbEt2WU1BWG9qbWhFcEVjYUwzaGtkY2JCb0dqajU1VmhJemNOeUdlZjlMNVZ5cHhJbnlYR2xaeldDT2k5NGc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc.'s (NASDAQ:ACOG) Path To Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVXlOXy1tem1FTlRqc1I2UTNrSmR2OWtCU1RVamNrSHFINzV4SFN5N3o5eEVET0RGcndLcU0wclh2LUlEb0JkMzhETjR5bUdJZGVrR0gxTUVIejhFYzJtWG5NNG1GRnRkalNxX0hjRkxkOHJENThzWUlPZTFNRzhUYmNSQ3lWSm1sQXBmSENPOEF6MU5zVFJncFV1ZTJ0RUdUNVE?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNelBDVk9QRl9iMWVGYjhnQlp2YzhJQlFVWldGTlBxeFdqTlJ4MWlyNnhjZE4xMXRiTkZ2V0R2TmJxaUhLclR3UFFHcEo5cHBtelFMaTR4dlFUZ0p1b1BiWnBXVndUN0dBWmZsSTZSUlYwOGcwblhaT0Z5WXFFZ2NMWHNBWVFoTnlHVmg1UGNB?oc=5", "source_name": "qz.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQcWhMSU8yZEZCaVY1RkV6RXdoWUZOeEpqOThrbktDNV9CRkhza1ZDeFBRSHQwYWZHbG1mSjE3dHc3Smp0SUpjdVRPcHdOVE5OSVhtdnRfUDIwOWV5cmpqcC1PSnMwcTFVSlFXYnluWnJ5RlplSEtneGMwMTA5VVdqcDlCRWJaMGpDMEFGOXMwZDNfQ2o2SWlRTlJpVl9qMlVoa1pENmVObGtVMFlDRjY2TEpScmw1bVFWOWRzTnI5SjQ2eDl3T1gzVg?oc=5", "source_name": "BioSpace", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALPHA COGNITION ($ACOG) Releases Q4 2025 Earnings | ACOG Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPbHc0MTJuMmhCZ3lVUzNsM3pGZkVRb18ta1BaR2VqbXpONWw3NkprN1hKbktlcGM1eU91ZjlIMmxsT3VQUjJxeHhQb0lVOGM4aWhFZ1pxc2VXb1AtQzc2WC1BcjhyNW9hVERBYWJlNkdheUFROER0WnYzQW5kWXZUN1pELURXdmdhQVJHMVN1bnZkUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNZ3FDN1ZZMFduTGxaUWZkWXBENlpDVEd5Y1hFcTBXZUJ3NEtLdE5HLWR5bXpRRzZ0MjhiZmdMV0NkTThFcWVJaUlRZHBiQkN0dkctcGVBNjhrZnRQMG0tLU9GOVVVdWtpRWV4d3FvM3NjRV9SaVlQN1BtWnB6cnZHNHExa2ozTGg1aTB2djBJek9EVWlJdzNlT0lUUW4yZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOekZTbUdSVEU0d2VYMk1HdTNqTnJWbG1fRWhYdlR1S0E0dGJiNUczNW8wTGxoa21oWTNhZFlrQV9VSGZzdUIwOFY5cE5HcWNEMEF5bkZ4bFUzNkNzckJ5Ulg3cFBuNE9lcElNRExQMkRUVEd2N0V4bDdFUWt5N1pNcDNVVnd5SGxTdGY4LXlmSU1hVnBDUjhXVUhONmRvWXdmMUJwejJlaV9KMl9oSTQ5aGZvbEdXV0dLRDZtaDVESUVlVEJpWmhlMVBDSlJUR1hrdnJhMjBOQkNwbnFSQTZ6U1d5eUpLVF94MnhTRERjUVBhYms?oc=5", "source_name": "Business Wire", "published_at": "2024-10-31T07:00:00+00:00", "published_display": "31 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approves Alpha Cognition\u2019s Zunveyl as Oral Therapy for Mild-to-Moderate Alzheimer Disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNdVVLY1A4dlk3Qk9yUGlTbFNTdktYZzJJZXlPRno3MXNOUWstRkFKUl9WMDg3OVNCYkdCQkpqNC1mel9yY08tRFVjUFJLTTNFNDJwd0hDZ040a211UHgtbDlfd2Q2d2pCM19UcnNHTkxrMDl1SFhqcDZJRzM4cjRzbDV3ZWVDWnpqOFpYVlVNb0l2YUJuOXJKWEJlRWl2b1JvX3JFUXR4cE9wZ3JYYUlfYmlB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2024-07-29T07:00:00+00:00", "published_display": "29 Jul 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 49, "sentiment_summary": {"positive": 17, "negative": 4, "neutral": 28, "score": 57, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 9.9, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 8.41, "latest_week": "2026-07-10", "one_week_move": 6.6, "four_week_move": 40.4, "twelve_week_move": 21.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.219123, "market_dynamics_buy_signal": false, "relative_strength": 6.42012, "fair_value_gap": 25.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 40.7555, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.6% over one week, +40.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 6}, {"label": "Business Wire", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "The Globe and Mail", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 5}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.6% over one week, +40.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Raymond James Starts Alpha Cognition (ACOG) at Outperform"}], "updated_at": "2026-07-16T05:12:24.836819+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}